Harvard Bioscience, Inc.
HBIOHarvard Bioscience, Inc. in brief
Harvard Bioscience, Inc. is a listed company in the Medical Instruments industry, based in Holliston, Massachusetts, USA. It was founded in 1901. Its market value was $38 M on 26 October 2026, which makes it the 22,291st largest listed company in the world and the 3,975th largest in the USA on this site. In the year to December 2025 it had sales of $87 M and a net loss of $57 M. John D. Duke is its chief executive. Its largest product and service lines by sales in 2025 were Instruments, Equipment, Software, and Accessories (90%) and Service, Maintenance, and Warranty Contracts (10%). By market, the largest shares of its 2025 sales came from USA (45%), EMEA (31%) and China (13%). Its shares trade under the symbol HBIO (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Harvard Bioscience, Inc.
Harvard Bioscience is a global developer, manufacturer and marketer of life sciences equipment to support research and drug discovery. It is traded on NASDAQ under the stock symbol HBIO.
Headquartered in Holliston, Massachusetts, United States, the company's brands include: Biochrom, BTX, CMA, Data Sciences International (DSI), Harvard Apparatus, HEKA, Hugo Sachs Elektronik, KD Scientific, Multi Channel Systems (MCS), Panlab, and Warner Instruments. The company has approximately 355 employees, with 216 of those in the USA, and its principal manufacturing facilities are in New Brighton, Minnesota, Holliston, Massachusetts, Reutlingen, Germany, Barcelona, Spain, and March, Germany.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
Harvard Bioscience, Inc. timeline
- 1901
- 🏁· approximateFounded
- 2000
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 🔔· approximateInitial public offering on Nasdaq as HBIO
Events of Harvard Bioscience, Inc. from Wikidata and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,606 (Jan 2020) · #3,370 (Jan 2021) · #3,565 (Jan 2022) · #4,161 (Dec 2022) · #3,206 (Jan 2024) · #2,286 (Mar 2026) · #3,871 (Aug 2026) · #3,978 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 0.4×
- Price / book
- 2.7×
- Free cash flow yield
- 14.5%
- Net margin (TTM)
- -13.2%
- Operating margin
- -56.1%
- Return on equity
- -85.9%
- Liabilities / assets
- 82.9%
- Net debt
- $27M
- Revenue growth
- -8.1%
- R&D / revenue
- 10.2%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $87M | -8.1% | $-49M | $-57M | -65.5% |
| Dec 2024 | $94M | -16.1% | $-6M | $-12M | -13.2% |
| Dec 2023 | $112M | -1.0% | $2M | $-3M | -3.0% |
| Dec 2022 | $113M | -4.7% | $-7M | $-10M | -8.4% |
| Dec 2021 | $119M | +16.5% | $2M | $-0M | -0.2% |
| Dec 2020 | $102M | -12.1% | $0M | $-8M | -7.6% |
| Dec 2019 | $116M | -3.8% | $0M | $-5M | -4.0% |
| Dec 2018 | $121M | — | $1M | $-3M | -2.4% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $7M | $1M | $5M | $-1.28 | — |
| Dec 2024 | $1M | $3M | $-1M | $-0.28 | — |
| Dec 2023 | $14M | $2M | $12M | $-0.08 | — |
| Dec 2022 | $1M | $2M | $-0M | $-0.23 | — |
| Dec 2021 | $1M | $1M | $0M | $-0.01 | — |
| Dec 2020 | $9M | $1M | $8M | $-0.20 | — |
| Dec 2019 | $8M | $1M | $7M | $-0.12 | — |
| Dec 2018 | $3M | $1M | $2M | $-0.08 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $22M (+7.8% on a year earlier), net income $-3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Nov 10, 20268-KCurrent reportRegulation FD disclosure
- Nov 10, 20268-KCurrent reportResults of operations
- Aug 11, 202610-QQuarterly report · period to Jun 2026
- Aug 11, 20268-KCurrent reportRegulation FD disclosure
- Aug 11, 20268-KCurrent reportResults of operations
- Jun 2, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- May 12, 202610-QQuarterly report · period to Mar 2026
- May 12, 20268-KCurrent reportRegulation FD disclosure
- May 12, 20268-KCurrent reportResults of operations
- Apr 21, 2026DEF 14AProxy statement
- Mar 17, 20268-KCurrent reportRegulation FD disclosure
Official filings of Harvard Bioscience, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $87 M
- Operating income
- $-49 M
- Net income
- $-57 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $80 M
- Total liabilities
- $66 M
- Total equity
- $14 M
As of December-2025
Top 30 institutional investors in Harvard Bioscience, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Weber Capital Management LLC /adv | 299,816 | -11,045 (-3.55%) | 6.56% | $2 M | Oct 19, 2026 |
| 2 | Acadian Asset Management LLC | 179,614 | 0 (0.00%) | 3.93% | $1 M | Nov 9, 2026 |
| 3 | Vanguard Capital Management LLC | 172,065 | +2,440 (+1.44%) | 3.76% | $1 M | Nov 13, 2026 |
| 4 | Mink Brook Asset Management LLC | 124,199 | +90,830 (+272.20%) | 2.72% | $1 M | Nov 13, 2026 |
| 5 | Corsair Capital Management, L.P. | 122,810 | 0 (0.00%) | 2.69% | $1 M | Nov 16, 2026 |
| 6 | Renaissance Technologies LLC | 94,327 | -5,000 (-5.03%) | 2.06% | $1 M | Nov 12, 2026 |
| 7 | Two Sigma Investments, LP | 85,535 | -29,010 (-25.33%) | 1.87% | $1 M | Nov 16, 2026 |
| 8 | BlackRock, Inc. | 61,893 | +59 (+0.10%) | 1.35% | $0 M | Nov 13, 2026 |
| 9 | Geode Capital Management, LLC | 46,753 | -802 (-1.69%) | 1.02% | $0 M | Nov 6, 2026 |
| 10 | Vanguard Fiduciary Trust Co | 27,730 | 0 (0.00%) | 0.61% | $0 M | Nov 13, 2026 |
| 11 | Millennium Management LLC | 27,060 | -5,560 (-17.04%) | 0.59% | $0 M | Nov 16, 2026 |
| 12 | Essex Investment Management Co LLC | 26,973 | 0 (0.00%) | 0.59% | $0 M | Oct 19, 2026 |
| 13 | Citadel Advisors LLC | 24,811 | +11,560 (+87.24%) | 0.54% | $0 M | Nov 16, 2026 |
| 14 | Williams & Novak Wealth Management, LLC | 16,555 | -4,394 (-20.97%) | 0.36% | $0 M | Oct 9, 2026 |
| 15 | RBF Capital, LLC | 16,000 | 0 (0.00%) | 0.35% | $0 M | Nov 13, 2026 |
| 16 | State Street Corp | 14,932 | 0 (0.00%) | 0.33% | $0 M | Nov 12, 2026 |
| 17 | UBS Group AG | 12,404 | -5,177 (-29.45%) | 0.27% | $0 M | Nov 10, 2026 |
| 18 | Gsa Capital Partners LLP | 11,499 | New | 0.25% | $0 M | Nov 16, 2026 |
| 19 | Dimensional Fund Advisors LP | 10,753 | New | 0.24% | $0 M | Nov 4, 2026 |
| 20 | Bank of New York Mellon Corp | 10,230 | 0 (0.00%) | 0.22% | $0 M | Nov 5, 2026 |
| 21 | Morgan Stanley | 9,909 | +8,282 (+509.04%) | 0.22% | $0 M | Nov 13, 2026 |
| 22 | FMR LLC | 3,086 | -93 (-2.93%) | 0.07% | $0 M | Nov 10, 2026 |
| 23 | Vanguard Global Advisers, LLC | 1,221 | 0 (0.00%) | 0.03% | $0 M | Nov 13, 2026 |
| 24 | SBI Securities Co., Ltd. | 866 | 0 (0.00%) | 0.02% | $0 M | Oct 22, 2026 |
| 25 | Brown Shipley& Co Ltd | 478 | 0 (0.00%) | 0.01% | $0 M | Oct 9, 2026 |
Show all 30: investors 26 to 30
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Tower Research Capital LLC (TRC) | 451 | -129 (-22.24%) | 0.01% | $0 M | Nov 16, 2026 |
| 27 | Nisa Investment Advisors, LLC | 228 | 0 (0.00%) | 0.01% | $0 M | Oct 20, 2026 |
| 28 | Royal Bank Of Canada | 129 | +114 (+760.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 29 | BNP Paribas Financial Markets | 66 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 30 | Jpmorgan Chase & Co | 32 | -163 (-83.59%) | 0.00% | $0 M | Nov 12, 2026 |
Mutual funds holding Harvard Bioscience, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 123,470 | $1 M | 2.7% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 42,043 | $0 M | 0.92% | <0.01% | +5.5% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 27,769 | $0 M | 0.61% | <0.01% | +24% | May 31, 2026 |
| 🇺🇸 Acuitas US Microcap FundAcuitas Investments, LLC | 13,380 | $0 M | 0.29% | 0.07% | — | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 7,017 | $0 M | 0.15% | <0.01% | −0.0% | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 5,946 | $0 M | 0.13% | <0.01% | +7.0% | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 4,112 | $0 M | 0.09% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 2,936 | $0 M | 0.06% | <0.01% | −0.0% | May 31, 2026 |
| 🇺🇸 Dimensional US Sustainability Core 1 ETFDimensional Fund Advisors LP | 1,902 | $0 M | 0.04% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 1,366 | $0 M | 0.03% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP | 1,229 | $0 M | 0.03% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 1,029 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP | 928 | $0 M | 0.02% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 683 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 LVIP Dimensional U.S. Core Equity 2 FundLincoln Financial Investments Corporation | 601 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 258 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 BlackRock Advantage Small Cap Core FundBlackRock Advisors, LLC | 30 | $0 M | <0.01% | <0.01% | −2.3% | May 29, 2026 |
| 🇺🇸 U.S. Sustainability Core 1 PortfolioDimensional Fund Advisors LP | 24 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 18 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Harvard Bioscience, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Katherine A. EadeDirector | Grant or award | +16,556 | — | — | 58,669 | Form 4 |
| filed | Robert E. GagnonDirector | Grant or award | +16,556 | — | — | 27,556 | Form 4 |
| filed | Seth Benjamin BensonDirector | Grant or award | +16,556 | — | — | 27,556 | Form 4 |
| filed | William SniderDirector | Grant or award | +16,556 | — | — | 48,556 | Form 4 |
| filed | Stephen J. DenelskyDirector | Grant or award | +16,556 | — | — | 37,556 | Form 4 |
| filed | Mark T. FrostChief Financial Officer | Grant or award | +30,000 | — | — | 47,500 | Form 4 |
| filed | John D. DukeChief Executive Officer, Director | Grant or award | +75,000 | — | — | 180,000 | Form 4 |
| filed | Stephen J. DenelskyDirector | Buy | +10,000 | $4.870 | $49 K | 21,000 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Harvard Bioscience, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 10-for-1 split
Trading halts
- 2026-03-13 23:50 UTC, code T3, resumed 13:00 UTC
Fails to deliver
- : 788 shares at $8.23
- : 837 shares at $6.37
- : 98 shares at $6.05
- : 359 shares at $5.40
- : 1,951 shares at $6.78
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Harvard Bioscience, Inc. scorecard#
Passes 6 of the 23 checks that could be worked out: strongest in valuation (3 of 6), weakest in growth (0 of 6). Fiscal year 2025; market cap of Oct 26, 2026.
Valuation3 of 6
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median2.7×Price to book 2.7× against Medical Instruments's median of 3.9×.
- ✓Price to sales below its peers' median0.4×Price to sales 0.4× against Medical Instruments's median of 3.0×.
- ✓Free cash flow yield above 5%14.5%Free cash flow is 14.5% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- ✗The price assumes slower growth than the last three years'0.7%The price assumes 0.7% a year for ten years; revenue grew -8.6% a year over the last three.
Growth0 of 6
- ✗Revenue grew in the newest year-8.1%Revenue down 8.1% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-8.6%-8.6% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-8.6%-8.6% a year against Medical Instruments's median of 5.0% (37 companies).
- ✗Earnings per share grew in the newest year-1.28 vs -0.28Diluted EPS -1.28 in fiscal 2025 against -0.28 the year before (report's currency).
- ✗Net income higher than five years earlier-$57 M-$57 M in fiscal 2025 against -$8 M in 2020.
- ✗Revenue rose in at least four of the last five years1 of 5Revenue rose in 1 of the five years to fiscal 2025.
Profitability0 of 5
- ✗Profitable in the newest year-$57 MNet income -$57 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-56.1%-56.1% against Medical Instruments's median of 7.2% (46 companies).
- ✗Return on equity above 15%-147.1%-147.1% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✗Operating margin wider than three years earlier-56.1%-56.1% in fiscal 2025 against -6.1% in 2022.
Financial health2 of 5
- ✓Short-term assets cover short-term liabilities2.2×Current ratio 2.20 at the end of fiscal 2025.
- ✗Debt below equity2.6×Debt to equity 2.61 at the end of fiscal 2025.
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-37.4×Operating income -37.4 times interest in fiscal 2025.
- ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-3.94Z-score -3.94 (distress zone) for fiscal 2025.
Shareholder returns1 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year2.0%Diluted shares up 2.0% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Medical Instruments, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Harvard Bioscience, Inc.'s statements, beside the median of Medical Instruments.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -56.1% | 7.2% | |
| Net margin | -65.5% | 3.8% | |
| Return on equity | -147.1% | 3.5% | |
| Revenue growth, 3 years a year | -8.6% | 5.0% | |
| Revenue growth | -8.1% | 8.9% | |
| Debt to equity | 2.61× | 0.46× |
5of 9on the Piotroski tests of financial strength
- Revenue fell 8.1% against the year before.
- Net loss of $57 million, the 11th loss-making year in a row.
- Operating income covers the interest bill only -37.4 times.
- Goodwill and intangibles ($17 million) exceed shareholders' equity ($14 million).
Harvard Bioscience, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 87−8.1%100% | 94−16.1%100% | 112−1.0%100% | 113−4.7%100% | 119+16.5%100% | 102−12.1%100% | 116−3.8%100% | 121+56.0%100% | 77r102−25.9%100% | 105—100% | |
| Cost of revenue | 37−6.9%42.3% | 39−14.7%41.8% | 46−12.1%41.1% | 53+2.5%46.3% | 51+16.3%43.1% | 44−15.0%43.2% | 52−10.0%44.6% | 58+50.6%47.7% | 38r54−31.8%49.4% | 56—53.7% | |
| Gross profit | 50−8.9%57.7% | 55−17.1%58.2% | 66+8.6%58.9% | 61−10.1%53.7% | 68+16.6%56.9% | 58−9.8%56.8% | 64+1.8%55.4% | 63+61.3%52.3% | 39r48−19.1%50.6% | 48—46.3% | |
| Research and development | 8.8−15.2%10.2% | 10−11.5%11.1% | 12−4.6%10.5% | 12+14.2%10.9% | 11+24.3%9.1% | 8.7−18.9%8.5% | 11−2.5%9.2% | 11+94.7%9.1% | 5.6+4.7%7.3% | 5.4—5.2% | |
| Selling and marketing | 19−13.5%22.2% | 22−7.7%23.6% | 24r24−3.9%21.4% | 25+1.6%22.1% | 25+23.7%20.7% | 20−14.4%19.5% | 23−4.8%20.0% | 24+62.1%20.2% | 15r21−26.4%19.5% | 20—19.6% | |
| General and administrative | 18−17.5%20.5% | 21−5.6%22.8% | 23r23−7.1%20.3% | 24+0.8%21.6% | 24+3.4%20.4% | 24+3.3%23.0% | 23+6.4%19.6% | 21+22.0%17.7% | 18r19−16.3%22.6% | 21—20.0% | |
| Operating expenses | 98+61.5%114% | 61−5.0%64.8% | 64−5.3%57.2% | 68+3.3%59.8% | 66+13.4%55.2% | 58−9.6%56.6% | 64+2.8%55.0% | 62+56.3%51.5% | 40r48−22.6%51.4% | 51—49.2% | |
| Operating income | −49—−56.1% | −6.2−428%−6.6% | 1.9—1.7% | −6.9−436%−6.1% | 2.1+835%1.7% | 0.2−41.4%0.2% | 0.4−61.7%0.3% | 1.0—0.8% | −0.6r−0.1—−0.8% | −3.0—−2.9% | |
| Interest expense and finance costs | 3.6+12.5%4.2% | 3.2—3.4% | — | — | — | — | — | 5.4+653%4.4% | 0.7+11.6%0.9% | 0.6r0.6—0.6% | |
| Other non-operating income (expense) | −8.8—−10.2% | −5.5—−5.8% | −4.5—−4.0% | −2.2—−2.0% | −2.2—−1.9% | −7.5—−7.4% | −5.9—−5.1% | −9.0—−7.4% | −2.0r−2.0—−2.6% | −0.1—−0.1% | |
| Income before tax | −57—−66.3% | −12—−12.4% | −2.6—−2.3% | −9.2—−8.1% | −0.1—−0.1% | −7.3—−7.1% | −5.5—−4.7% | −8.0—−6.6% | −2.6r−2.1—−3.4% | −3.1—−2.9% | |
| Income tax | −0.7−193%−0.8% | 0.7−13.9%0.8% | 0.9+155%0.8% | 0.3+128%0.3% | 0.1−71.4%0.1% | 0.5—0.5% | −0.8—−0.7% | −3.7—−3.0% | −0.6r−1.2−149%−0.8% | 1.2—1.2% | |
| Income from continuing operations | — | — | — | — | — | — | −4.7—−4.0% | −4.3—−3.6% | −2.0—−2.6% | — | |
| Income from discontinued operations | — | — | — | — | — | — | — | 1.4+19.6%1.1% | 1.2—1.5% | — | |
| Net income attributable to shareholders | −57—−65.5% | −12—−13.2% | −3.4—−3.0% | −9.5—−8.4% | −0.3—−0.2% | −7.8—−7.6% | −4.7—−4.0% | −2.9—−2.4% | −0.9—−1.1% | −4.3—−4.1% | |
| Earnings per share, basic | -1.28—— | -0.28—— | -0.08—— | -0.23—— | -0.01—— | -0.20—— | -0.12—— | -0.08—— | -0.02—— | -0.13—— | |
| Earnings per share, diluted | -1.28—— | -0.28—— | -0.08—— | -0.23—— | -0.01—— | -0.20—— | -0.12—— | -0.08—— | -0.02—— | -0.13—— | |
| Shares, weighted average (basic) | 44+2.0%— | 44+2.6%— | 42+2.4%— | 41+2.7%— | 40+4.4%— | 39r39+2.2%— | 38+3.7%— | 36+4.9%— | 35+1.6%— | 34—— | |
| Shares, weighted average (diluted) | 44+2.0%— | 44+2.6%— | 42+2.4%— | 41+2.7%— | 40+4.4%— | 39r39+2.2%— | 38+3.7%— | 36+4.9%— | 35+1.6%— | 34—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 8.6+110%10.8% | 4.1−4.1%3.2% | 4.3−5.0%3.1% | 4.5−42.4%3.1% | 7.8−6.0%4.8% | 8.3−0.2%5.3% | 8.3+2.0%5.1% | 8.2+42.6%4.8% | 5.7r5.7+2.4%5.2% | 5.6—5.2% | |
| Receivables | 16+7.9%20.0% | 15−7.7%11.7% | 16−3.6%11.7% | 17−23.5%11.5% | 22+22.9%13.4% | 18−14.2%11.4% | 21−3.5%12.6% | 21+60.4%12.7% | 13r16−15.0%12.2% | 16—14.6% | |
| Inventory | 21−10.5%26.0% | 23−6.0%18.4% | 25−6.5%18.0% | 26−4.2%18.2% | 28+23.9%17.0% | 22+0.9%14.2% | 22−12.1%13.4% | 25+48.9%14.9% | 17r21−15.6%15.4% | 20—18.5% | |
| Other current assets | 2.8−4.7%3.5% | 2.9−26.4%2.3% | 3.9+13.5%2.9% | 3.5−20.0%2.4% | 4.3+29.4%2.7% | 3.4+35.7%2.1% | 2.5−20.5%1.5% | 3.1−16.2%1.8% | 3.7r4.2−11.2%3.4% | 4.2—3.9% | |
| Current assets | 48+6.9%60.2% | 45−8.0%35.6% | 49−4.1%35.7% | 51−17.0%35.2% | 62+19.1%37.9% | 52−3.5%33.1% | 54−7.4%32.5% | 58+21.7%34.3% | 48+4.5%43.5% | 45—42.2% | |
| Property, plant and equipment | 4.8−6.2%6.0% | 5.1+28.3%4.0% | 4.0+18.3%2.9% | 3.4−1.4%2.3% | 3.4−13.8%2.1% | 4.0−17.1%2.5% | 4.8−19.0%2.9% | 5.9+57.6%3.5% | 3.7r4.1−12.9%3.4% | 4.3—4.0% | |
| Right-of-use (leased) assets | 7.2+17.0%9.0% | 6.1+28.5%4.8% | 4.8−17.9%3.5% | 5.8−15.7%4.0% | 6.9−11.1%4.2% | 7.8−8.3%5.0% | 8.5—5.1% | 0—0.0% | — | — | |
| Goodwill | 9.6−83.0%11.9% | 56−1.3%44.5% | 57+1.4%41.5% | 56−2.5%38.7% | 58−1.5%35.5% | 59+2.1%37.5% | 57+0.1%34.8% | 57+57.7%34.0% | 36r40−4.5%33.2% | 38—35.3% | |
| Other intangible assets | 7.6−31.4%9.5% | 11−30.6%8.8% | 16−23.7%11.7% | 21−23.3%14.5% | 27−17.4%16.9% | 33−13.7%21.2% | 38−16.1%23.3% | 46r45+356%27.1% | 10r16−42.6%9.2% | 17—16.2% | |
| Total assets | 80−36.8%100% | 127−7.8%100% | 137−5.5%100% | 145−10.5%100% | 162+3.9%100% | 156−5.2%100% | 165−2.2%100% | 169+54.2%100% | 109+1.5%100% | 108—100% | |
| Accounts payable | 3.7−23.7%4.6% | 4.8−13.8%3.8% | 5.6−13.9%4.0% | 6.4+31.3%4.4% | 4.9−17.8%3.0% | 6.0+11.9%3.8% | 5.3−27.4%3.2% | 7.4+66.9%4.4% | 4.4r5.4−28.8%4.0% | 6.2—5.7% | |
| Debt due within a year | 0−100%0.0% | 37r37+502%29.2% | 6.1+50.1%4.5% | 4.1+16.4%2.8% | 3.5+75.8%2.2% | 2.0−37.5%1.3% | 3.2+33.3%1.9% | 2.4—1.4% | — | — | |
| Current liabilities | 22−60.0%27.4% | 55+107%43.4% | 27+14.2%19.3% | 23−8.2%16.0% | 25+20.2%15.6% | 21−16.8%13.5% | 25−0.7%15.4% | 25r22+81.5%15.1% | 14−3.8%12.8% | 15—13.5% | |
| Long-term debt | 36—44.8% | 0−100%0.0% | 31−28.6%22.4% | 43−4.6%29.6% | 45−2.6%27.8% | 46−1.3%29.6% | 47−14.4%28.5% | 55r59+510%32.5% | 9.0−21.0%8.2% | 11—10.6% | |
| Lease liabilities (non-current) | 6.9+7.9%8.6% | 6.4+33.1%5.0% | 4.8−9.2%3.5% | 5.3−18.6%3.6% | 6.5−13.3%4.0% | 7.5−9.0%4.8% | 8.2—5.0% | 0—0.0% | — | — | |
| Total liabilities | 66+4.8%82.8% | 63−1.5%50.0% | 64−12.1%46.8% | 73−7.4%50.3% | 79−0.8%48.6% | 80−4.3%50.9% | 83−3.2%50.4% | 86+202%50.9% | 28−20.0%26.0% | 36—33.0% | |
| Retained earnings | −215—−268% | −158—−125% | −146—−106% | −142—−97.8% | −133—−81.7% | −132—−84.7% | −125—−75.6% | −120—−71.1% | −117—−107% | −116—−108% | |
| Shareholders' equity | 14−78.3%17.2% | 63r63−13.3%50.0% | 73+1.2%53.2% | 72−13.4%49.7% | 83+8.8%51.4% | 77−6.1%49.1% | 82−1.2%49.6% | 83+2.3%49.1% | 81+12.1%74.0% | 72—67.0% | |
| Total liabilities and equity | 80−36.8%100% | 127−7.8%100% | 137−5.5%100% | 145−10.5%100% | 162+3.9%100% | 156−5.2%100% | 165−2.2%100% | 169+54.2%100% | 109+1.5%100% | 108—100% | |
| Shares outstanding | 4.5r45−89.9%— | 44+1.6%— | 43+3.1%— | 42+2.3%— | 41+4.4%— | 39+3.2%— | 38+2.2%— | 37+6.7%— | 350.0%— | 35r34—— | |
| Cash-flow statement | |||||||||||
| Share-based compensation | 1.9−57.3%2.1% | 4.3−13.2%4.6% | 5.0+13.4%4.5% | 4.4+5.8%3.9% | 4.2+14.3%3.5% | 3.6+20.2%3.6% | 3.0−0.3%2.6% | 3.0−13.0%2.5% | 3.5+0.1%4.5% | 3.5—3.3% | |
| Cash from operating activities | 6.7+367%7.8% | 1.4−89.7%1.5% | 14+1118%12.5% | 1.2−8.7%1.0% | 1.3−86.5%1.1% | 9.3+16.0%9.1% | 8.0+179%6.9% | 2.9+173%2.4% | 1.1−80.4%1.4% | 5.4—5.2% | |
| Capital expenditure | −1.3—−1.5% | −2.6—−2.8% | −1.8—−1.6% | −1.6—−1.4% | −1.2—−1.0% | −1.2—−1.1% | −1.2—−1.0% | −1.0—−0.8% | −0.9—−1.1% | — | |
| Intangible assets bought | −0.6—−0.7% | −0.6—−0.7% | −0.5—−0.5% | 0—0.0% | −0.2—−0.1% | −0.3—−0.2% | — | — | — | — | |
| Acquisitions, net of cash acquired | — | — | — | — | — | — | — | −69—−56.8% | 0—0.0% | 0—0.0% | |
| Cash from investing activities | −1.9—−2.2% | −1.3—−1.4% | −1.8—−1.6% | −1.6—−1.4% | −1.3—−1.1% | −1.4—−1.4% | −0.2—−0.2% | −54—−44.5% | −0.9—−1.2% | −0.1—−0.1% | |
| Debt issued | 40—46.2% | 0—0.0% | — | — | — | — | — | — | — | — | |
| Debt repaid | −25—−28.5% | −6.0—−6.4% | −4.1—−3.6% | −3.2—−2.8% | −2.0r−4.2—−1.7% | −67—−65.5% | −12—−10.1% | −20—−16.7% | −4.7—−6.1% | −9.1—−8.7% | |
| Shares issued | — | — | — | — | — | — | — | 4.6+2748%3.8% | 0.2−12.1%0.2% | 0.2—0.2% | |
| Cash from financing activities | −1.3—−1.5% | −0.1—−0.1% | −12—−10.8% | −2.8—−2.5% | −0.3—−0.2% | −8.0—−7.8% | −7.6−114%−6.6% | 53—43.9% | −1.8—−2.3% | −4.9—−4.7% | |
| Exchange-rate effect on cash | — | — | — | — | — | — | — | 0.3−83.3%0.2% | 1.8—2.3% | −1.6—−1.5% | |
| Change in cash | 4.5—5.2% | −0.2—−0.2% | −0.2—−0.2% | −3.3—−2.9% | −0.5—−0.4% | −0.0−111%−0.0% | 0.2−93.4%0.1% | 2.4+1681%2.0% | 0.1—0.2% | −1.1—−1.1% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K/A | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 89+2.3%100% | 22+7.8%100% | 23+11.1%100% | 21−4.7%100% | 24*−3.3%100% | 21−6.3%100% | 20−11.5%100% | 22−11.2%100% | 25*−12.8%100% | 22r22—100% | 23—100% | 25—100% | 28*—100% | |
| Cost of revenue | 38+1.2%42.6% | 9.9+15.4%44.6% | 10+13.2%44.4% | 8.5−11.3%41.0% | 9.6*−9.3%40.3% | 8.6−6.9%41.6% | 8.9−9.7%43.6% | 9.6−1.5%44.0% | 11*−10.8%42.9% | 9.2—41.9% | 9.9—42.8% | 9.7—39.7% | 12*—42.0% | |
| Gross profit | 51+3.2%57.4% | 12+2.4%55.4% | 13+9.5%55.6% | 12+0.5%59.0% | 14*+1.1%59.7% | 12−5.8%58.4% | 12−12.7%56.4% | 12−17.5%56.0% | 14*−14.2%57.1% | 13—58.1% | 13—57.2% | 15—60.3% | 16*—58.0% | |
| Research and development | 9.2+2.8%10.3% | 2.3+5.9%10.2% | 2.5+12.1%10.8% | 2.3+0.2%11.2% | 2.2*−6.2%9.2% | 2.1−16.9%10.4% | 2.2−16.6%10.7% | 2.3−19.5%10.7% | 2.3*−26.1%9.5% | 2.6—11.7% | 2.6—11.4% | 2.9—11.8% | 3.2*—11.2% | |
| Selling and marketing | 21+8.9%23.8% | 5.4+17.5%24.4% | 5.4+19.0%23.8% | 5.3+7.3%25.7% | 5.1*−5.6%21.5% | 4.6−16.4%22.4% | 4.5−15.9%22.2% | 5.0−15.8%22.8% | 5.4*−12.6%22.0% | 5.5—25.1% | 5.4—23.4% | 5.9—24.1% | 6.2r6.2*—21.9% | |
| General and administrative | 18−1.3%20.3% | 4.8+13.9%21.4% | 4.6+8.3%20.3% | 4.7−9.3%22.7% | 4.1*−14.2%17.4% | 4.2−17.2%20.3% | 4.3−25.0%20.8% | 5.2−13.0%23.8% | 4.8*−8.7%19.6% | 5.0—22.9% | 5.7—24.6% | 6.0—24.3% | 5.3r5.3*—18.7% | |
| Operating expenses | 53−47.1%59.2% | 13+13.8%60.6% | 14+10.2%59.9% | 13−78.3%64.6% | 12*−11.0%52.5% | 12−19.2%57.4% | 12−19.2%60.4% | 62+263%284% | 14*−12.7%57.0% | 15—66.6% | 15—66.2% | 17—69.6% | 16*—57.0% | |
| Operating income | −1.6—−1.8% | −1.2−684%−5.2% | −1.0—−4.3% | −1.2—−5.7% | 1.7*+15445%7.2% | 0.2—1.0% | −0.8—−4.0% | −50—−228% | 0.0*−96.1%0.0% | −1.9—−8.5% | −2.1—−9.0% | −2.3—−9.3% | 0.3*—1.0% | |
| Interest expense and finance costs | — | 1.3+30.0%5.9% | 1.3+62.5%5.7% | — | 1.0*—4.2% | 1.0—4.9% | 0.8—3.9% | — | — | — | — | — | — | |
| Other non-operating income (expense) | −11—−11.8% | −1.5—−7.0% | −1.9—−8.4% | −2.1—−10.3% | −4.9*−949%−20.7% | −1.3—−6.5% | −1.4—−7.0% | −1.1—−5.2% | 0.6*—2.4% | −2.6—−11.9% | −1.2—−5.2% | −2.2—−9.0% | −1.4*—−4.9% | |
| Income before tax | −12—−13.5% | −2.7—−12.1% | −2.9—−12.7% | −3.3—−15.9% | −3.2*−643%−13.5% | −1.1—−5.5% | −2.3—−11.0% | −51—−233% | 0.6*—2.4% | −4.5—−20.4% | −3.3—−14.2% | −4.5—−18.3% | −1.1*—−3.9% | |
| Income tax | −0.3−223%−0.3% | −0.1−174%−0.3% | 0.0−50.0%0.1% | 0.1—0.6% | −0.4*−162%−1.5% | 0.1−68.8%0.5% | 0.0—0.1% | −0.5−316%−2.1% | 0.6*−20.0%2.3% | 0.3—1.4% | −0.4—−1.5% | 0.2—0.9% | 0.7*—2.5% | |
| Net income attributable to shareholders | −12—−13.2% | −2.6—−11.8% | −2.9—−12.8% | −3.4—−16.5% | −2.8*−15917%−12.0% | −1.2—−6.0% | −2.3—−11.2% | −50—−231% | 0.0*—0.1% | −4.8—−21.9% | −2.9—−12.7% | −4.7—−19.1% | −1.8*—−6.5% | |
| Earnings per share, basic | — | -0.58—— | -0.64—— | -0.77—— | — | -0.28r-0.03—— | -0.52r-0.05—— | -11.42r-1.14—— | — | -0.11—— | -0.07—— | -0.11—— | — | |
| Earnings per share, diluted | — | -0.58—— | -0.64—— | -0.77—— | — | -0.28r-0.03—— | -0.52r-0.05—— | -11.42r-1.14—— | — | -0.11—— | -0.07—— | -0.11—— | — | |
| Shares, weighted average (basic) | 4.6+2.4%— | 4.6+2.4%— | 4.5+2.2%— | 4.5+1.4%— | — | 4.5r45−89.8%— | 4.4r44−89.8%— | 4.4r44−89.8%— | — | 44—— | 43—— | 43—— | — | |
| Shares, weighted average (diluted) | 4.6+2.4%— | 4.6+2.4%— | 4.5+2.2%— | 4.5+1.4%— | — | 4.5r45−89.8%— | 4.4r44−89.8%— | 4.4r44−89.8%— | — | 44—— | 43—— | 43—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 4.9—6.4% | 4.9−28.8%6.4% | 6.5−12.6%8.5% | 7.1+28.0%9.1% | 8.6+110%10.8% | 6.8+49.2%8.7% | 7.4+83.8%9.3% | 5.5+30.3%6.9% | 4.1−4.1%3.2% | 4.6—3.5% | 4.0—3.1% | 4.3—3.2% | 4.3—3.1% | |
| Receivables | 15—19.8% | 15+23.1%19.8% | 15+21.5%19.0% | 15+8.1%18.7% | 16+7.9%20.0% | 12−5.6%15.5% | 12−4.4%14.9% | 13−12.0%16.9% | 15−7.7%11.7% | 13—9.8% | 12—9.7% | 15—11.5% | 16—11.7% | |
| Inventory | 23—31.2% | 23+8.7%31.2% | 22−0.1%29.1% | 22−2.7%28.5% | 21−10.5%26.0% | 22−16.9%27.7% | 22−11.4%27.8% | 23−5.5%28.6% | 23−6.0%18.4% | 26—19.8% | 25—19.5% | 24—18.1% | 25—18.0% | |
| Other current assets | 2.7—3.6% | 2.7−17.0%3.6% | 3.2−3.1%4.2% | 3.6+17.7%4.6% | 2.8−4.7%3.5% | 3.3−3.7%4.2% | 3.3−30.0%4.2% | 3.1−31.2%3.8% | 2.9−26.4%2.3% | 3.4—2.6% | 4.8—3.7% | 4.4—3.3% | 3.9—2.9% | |
| Current assets | 46—61.1% | 46+5.0%61.1% | 46+3.3%60.9% | 47+5.7%60.9% | 48+6.9%60.2% | 44−6.4%56.2% | 45−3.1%56.1% | 45−6.7%56.3% | 45−8.0%35.6% | 47—35.7% | 46—36.0% | 48—36.2% | 49—35.7% | |
| Property, plant and equipment | 5.4—7.2% | 5.4+8.2%7.2% | 5.3+8.8%7.0% | 4.9−2.8%6.2% | 4.8−6.2%6.0% | 5.0−4.4%6.4% | 4.9+3.3%6.1% | 5.0+11.5%6.3% | 5.1+28.3%4.0% | 5.2—4.0% | 4.8—3.7% | 4.5—3.4% | 4.0—2.9% | |
| Right-of-use (leased) assets | 6.0—7.9% | 6.0−20.3%7.9% | 6.4−10.3%8.4% | 6.7−7.6%8.6% | 7.2+17.0%9.0% | 7.5+15.0%9.6% | 7.1+61.3%8.9% | 7.3+67.1%9.1% | 6.1+28.5%4.8% | 6.5—5.0% | 4.4—3.4% | 4.4—3.3% | 4.8—3.5% | |
| Goodwill | 9.3—12.4% | 9.3−2.4%12.4% | 9.3−8.1%12.2% | 9.4+4.6%12.0% | 9.6−83.0%11.9% | 9.5−83.4%12.2% | 10−82.1%12.7% | 9.0−84.2%11.2% | 56−1.3%44.5% | 57—43.8% | 57—43.9% | 57—42.6% | 57—41.5% | |
| Other intangible assets | 6.2—8.2% | 6.2−26.2%8.2% | 6.2−31.9%8.2% | 6.9−31.8%8.9% | 7.6−31.4%9.5% | 8.4−32.1%10.7% | 9.1−32.0%11.4% | 10−31.0%12.7% | 11−30.6%8.8% | 12—9.4% | 13—10.4% | 15—11.0% | 16—11.7% | |
| Total assets | 75—100% | 75−3.5%100% | 76−4.8%100% | 78−2.3%100% | 80−36.8%100% | 78−40.6%100% | 80−37.9%100% | 80−40.1%100% | 127−7.8%100% | 131—100% | 129—100% | 133—100% | 137—100% | |
| Accounts payable | 7.2—9.5% | 7.2+38.3%9.5% | 6.2+31.8%8.2% | 5.3+10.0%6.8% | 3.7−23.7%4.6% | 5.2−2.0%6.6% | 4.7−17.3%5.9% | 4.8−20.5%6.0% | 4.8−13.8%3.8% | 5.3—4.0% | 5.7—4.4% | 6.0—4.5% | 5.6—4.0% | |
| Debt due within a year | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0−100%0.0% | — | — | — | 37r37+502%29.2% | 4.0—3.0% | 4.0—3.1% | 4.0—3.0% | 6.1—4.5% | |
| Current liabilities | 26—34.7% | 26−52.0%34.7% | 25−55.1%32.5% | 24−57.1%30.6% | 22−60.0%27.4% | 54+139%69.7% | 55+144%68.9% | 56+117%69.7% | 55+107%43.4% | 23—17.3% | 23—17.5% | 26—19.3% | 27—19.3% | |
| Long-term debt | 37—49.3% | 37—49.3% | 37—48.1% | 36—46.5% | 36—44.8% | — | — | — | 0−100%0.0% | 34—26.1% | 32—24.8% | 32—23.9% | 31—22.4% | |
| Lease liabilities (non-current) | 5.4—7.2% | 5.4−25.8%7.2% | 5.9−15.3%7.8% | 6.4−12.0%8.2% | 6.9+7.9%8.6% | 7.3+9.3%9.4% | 7.0+48.5%8.7% | 7.2+58.7%9.1% | 6.4+33.1%5.0% | 6.7—5.1% | 4.7—3.7% | 4.6—3.4% | 4.8—3.5% | |
| Total liabilities | 70—93.2% | 70+9.8%93.2% | 69+7.0%90.3% | 68+4.5%87.1% | 66+4.8%82.8% | 64−3.0%82.0% | 64+4.4%80.4% | 65+1.0%81.4% | 63−1.5%50.0% | 66—50.2% | 62—47.8% | 64—48.3% | 64—46.8% | |
| Retained earnings | −224—−297% | −224—−297% | −221—−290% | −218—−280% | −215—−268% | −212—−272% | −211—−263% | −208—−261% | −158—−125% | −158—−120% | −153—−119% | −150—−113% | −146—−106% | |
| Shareholders' equity | 5.1—6.8% | 5.1−63.7%6.8% | 7.4−52.9%9.7% | 10−32.3%12.9% | 14−78.3%17.2% | 14−78.5%18.0% | 16−76.6%19.6% | 15−78.4%18.6% | 63r63−13.3%50.0% | 65—49.8% | 67—52.2% | 69—51.7% | 73—53.2% | |
| Total liabilities and equity | 75—100% | 75−3.5%100% | 76−4.8%100% | 78−2.3%100% | 80−36.8%100% | 78−40.6%100% | 80−37.9%100% | 80−40.1%100% | 127−7.8%100% | 131—100% | 129—100% | 133—100% | 137—100% | |
| Shares outstanding | 4.6—— | 4.6−89.7%— | 4.6−89.8%— | 4.5−89.8%— | 4.5r45−89.9%— | 45+2.2%— | 45+2.1%— | 44+1.8%— | 44+1.6%— | 44—— | 44—— | 43—— | 43—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 1.5−35.0%1.7% | 0.4+34.6%2.0% | 0.4−19.5%1.7% | 0.3−57.2%1.2% | 0.5*−52.2%1.9% | 0.3−69.2%1.6% | 0.5−63.1%2.3% | 0.6−42.7%2.8% | 1.0*−30.5%3.9% | 1.1*—4.8% | 1.3*—5.5% | 1.0—4.3% | 1.4*—4.9% | |
| Cash from operating activities | −0.7−108%−0.8% | −0.2*−123%−1.1% | 0.3*−88.2%1.4% | −0.7−122%−3.2% | −0.1*−106%−0.4% | 1.1*—5.3% | 2.8*—13.5% | 3.0+113%13.7% | 1.7*−59.9%7.0% | −0.8*—−3.8% | −0.8*—−3.7% | 1.4—5.7% | 4.3*—15.3% | |
| Capital expenditure | −2.5—−2.8% | −0.9*—−4.2% | −0.7*—−3.0% | −0.4—−2.1% | −0.4*—−1.9% | −0.2*—−1.0% | −0.1*—−0.4% | −0.5—−2.4% | −0.3*—−1.2% | −0.9*—−4.0% | −0.8*—−3.5% | −0.6—−2.6% | −0.8*—−2.9% | |
| Intangible assets bought | −1.0—−1.1% | −0.4*—−1.9% | −0.2*—−1.0% | −0.2—−0.9% | −0.2*—−0.6% | −0.1*—−0.7% | −0.1*—−0.7% | −0.2—−0.8% | −0.2*—−0.7% | −0.2*—−1.1% | −0.1*—−0.6% | −0.1—−0.3% | −0.2*—−0.8% | |
| Cash from investing activities | −3.5—−3.9% | −1.3*—−6.1% | −0.9*—−4.0% | −0.6—−3.0% | −0.6*—−2.5% | −0.3*—−1.7% | −0.2*−151%−1.1% | −0.7—−3.1% | −0.5*—−1.9% | −1.1*—−5.1% | 0.5*—2.0% | −0.2—−0.9% | −1.1*—−3.8% | |
| Debt repaid | −22—−24.3% | 0*—0.0% | 0*—0.0% | 0—0.0% | −22*—−91.4% | −1.0*—−4.9% | −1.0*—−4.9% | −1.0—−4.6% | −1.0*—−4.1% | −1.0*—−4.6% | −1.0*—−4.3% | −3.0—−12.3% | −0.8*—−2.7% | |
| Cash from financing activities | 2.4—2.6% | −0.0*—−0.2% | −0.0*—−0.2% | −0.0—−0.0% | 2.4*—10.3% | −1.3*−161%−6.2% | −1.3*−811%−6.2% | −1.2—−5.5% | −1.4*—−5.5% | 2.1*—9.6% | 0.2*—0.8% | −1.1—−4.3% | −4.1*—−14.6% | |
| Change in cash | −2.0−187%−2.2% | −1.6*—−7.4% | −0.6*−131%−2.6% | −1.5−205%−7.3% | 1.8*—7.6% | −0.6*−220%−3.0% | 1.9*—9.3% | 1.4—6.6% | −0.5*—−1.9% | 0.5*—2.4% | −0.2*—−0.9% | −0.0—−0.1% | −1.1*—−3.8% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Harvard Bioscience, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Instruments, Equipment, Software, and Accessories$78 M90%-10%
- Service, Maintenance, and Warranty Contracts$8 M9.6%+16%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Where Harvard Bioscience, Inc. operates: 2 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at Harvard Bioscience, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025John D. Duke | $905 K | $2.3 M | $344 K | $10 |
| 2024John D. Duke | $2.3 M | −$2.0 M | $603 K | $30 |
| 2023John D. Duke | $2.4 M | $7.2 M | $571 K | $76 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Harvard Bioscience, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 3 · Restructuring 1 · Directors and officers 9 · Material agreement 2 · Agreement ended 1 · New debt 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 8
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Restructuring | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Directors and officersMaterial agreementAgreement endedNew debt | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Delisting notice | 8-K/A | |
| Delisting notice | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Government contracts: Harvard Bioscience, Inc.#
$1.6 M in federal contracts in fiscal 2026, mostly from Department of Defense and Department of Health and Human Services.
- Department of Defense$1.2 M
- Department of Health and Human Services$233 K
- Department of Veterans Affairs$180 K
| Fiscal year | Contracts | Grants |
|---|---|---|
| FY2026 | $1.6 M | — |
| FY2025 | $1.6 M | — |
| FY2024 | $1.9 M | — |
| FY2023 | $1.8 M | — |
| FY2022 | $1.1 M | — |
| FY2021 | $1.6 M | — |
| FY2020 | $1.8 M | — |
| FY2019 | $3.1 M | — |
| FY2018 | $2.4 M | — |
| FY2017 | $2.5 M | — |
| FY2016 | $1.1 M | — |
| FY2015 | $1.1 M | — |
| FY2014 | $404 K | — |
| FY2013 | $342 K | — |
| FY2012 | $140 K | — |
| FY2011 | $363 K | — |
| FY2010 | $249 K | $421 K |
| FY2009 | $168 K | $363 K |
| FY2008 | $133 K | — |
Source: USAspending.gov. Obligations are binding promises to pay, not payments, and can be negative when an award is cut. Counted under Harvard Bioscience, Inc.: HARVARD BIOSCIENCE INC (UEI CS6JFXF1C373)
H-1B hiring at Harvard Bioscience, Inc.#
1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $141 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Engineering Manager, Firmware & Software TeamInformation Technology Project Managers | 1 | $141 K |
Where: Holliston, MA 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2026 | 1 | 1 | $141 K | 1 |
| FY2025 | 3 | 3 | $82 K | 3 |
| FY2024 | 4 | 4 | $77 K | 4 |
| FY2023 | 4 | 4 | $89 K | 4 |
| FY2022 | 4 | 4 | $83 K | 4 |
| FY2021 | 3 | 3 | $80 K | 3 |
| FY2020 | 3 | 3 | $84 K | 3 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Harvard Bioscience Inc.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | · | · | · | · | · | · | · | · | · | · | · | — | |
| 2019 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| 2015 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| 2013 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| 2008 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing | |
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing | |
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing | |
| 13% of workforce | Restructuring planSEC 8-K | “The Company committed to the realignment plan on December 3, 2013, which will include reducing its workforce by approximately 13 percent by eliminating certain operational redundan…” | Filing | |
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing | |
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Harvard Bioscience, Inc. compares in Medical Instruments
- Market cap$38 M · higher than 7% of 116
- Revenue$87 M · higher than 18% of 120
- Net margin-13.2% · higher than 12% of 114
- Revenue growth-8.1% · higher than 8% of 49
- Price / sales0.4× · lower than 98% of 85
- Price / book2.7× · lower than 59% of 84
- FCF yield14.5% · highest of 39
Peer comparison · Medical Instruments
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Harvard Bioscience, Inc.🇺🇸 | $38 M | — | -13.2% | -8.1% |
| Intuitive Surgical, Inc.🇺🇸 | $155.6 B | 52.6× | 25.5% | +20.5% |
| EssilorLuxottica S.A.🇫🇷 | $88.0 B | 32.1× | 8.1% | +4.5% |
| HOYA Corporation🇯🇵 | $56.2 B | 32.8× | 25.4% | — |
| Becton, Dickinson and Company🇺🇸 | $54.0 B | 57.4× | 4.2% | +8.2% |
| Alcon Inc.🇨🇭 | $37.1 B | 37.9× | 9.4% | +4.9% |
| ResMed Inc.🇺🇸 | $35.3 B | 22.1× | 27.8% | +9.8% |
| West Pharmaceutical Services, Inc.🇺🇸 | $27.1 B | 42.4× | 18.8% | +6.3% |
| Terumo Corporation🇯🇵 | $24.9 B | 27.0× | 12.0% | — |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 26, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, Wikipedia, Wikimedia Commons, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Harvard Bioscience, Inc.? Verify and update this profile — free
Show Harvard Bioscience, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.